ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS

ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS

Despite significant advances in recent years, the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) continues to present major clinical challenges. Existing therapies offer limited efficacy for many patients, particularly those with high-risk disease, highlighting a substantial unmet medical need.
ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL

ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL

The treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a major clinical challenge. While CAR-T cell therapy can induce rapid and deep remissions, many patients continue to face a substantial risk of relapse. Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy has emerged as a promising curative strategy. However, evidence regarding its long-term efficacy, optimal timing, and the role of molecular biomarkers in guiding treatment decisions has remained limited.
COMy 2026 | Professor Nizar Bahlis: A Comprehensive Framework for Understanding and Overcoming Bispecific Antibody Resistance in Multiple Myeloma

COMy 2026 | Professor Nizar Bahlis: A Comprehensive Framework for Understanding and Overcoming Bispecific Antibody Resistance in Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential global meetings in the field of multiple myeloma (MM), the congress brought together leading investigators to discuss the latest advances in translational research, innovative therapies, and patient care.
COMy 2026 | Professor Philippe Moreau: Thirty-Five Years of Progress—Tracing the Evolution of Frontline Therapy for Transplant-Eligible Multiple Myeloma

COMy 2026 | Professor Philippe Moreau: Thirty-Five Years of Progress—Tracing the Evolution of Frontline Therapy for Transplant-Eligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in research, innovative therapies, and patient care.
COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma (MM), the congress brought together leading experts from around the world to discuss the latest advances in research, novel therapies, and patient care.
COMy 2026 | Professor Shaji Kumar: An Early Look at the Landmark Changes in the New Multiple Myeloma Response Criteria

COMy 2026 | Professor Shaji Kumar: An Early Look at the Landmark Changes in the New Multiple Myeloma Response Criteria

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential global meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in translational research, novel therapeutics, and patient care.
COMy 2026 | Professor Steven P. Treon: The Precision Era of Waldenström Macroglobulinemia—Overcoming Resistance and Exploring New Therapeutic Targets

COMy 2026 | Professor Steven P. Treon: The Precision Era of Waldenström Macroglobulinemia—Overcoming Resistance and Exploring New Therapeutic Targets

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma and related plasma cell disorders, the congress brought together leading experts worldwide to discuss the latest advances in translational research, novel therapeutics, and patient care.